Deka Bank Deutsche Girozentrale Madrigal Pharmaceuticals, Inc. Transaction History

Deka Bank Deutsche Girozentrale

$53.9 Billion
Q3 2024

A detailed history of Deka Bank Deutsche Girozentrale transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Deka Bank Deutsche Girozentrale holds 8,000 shares of MDGL stock, worth $2.71 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,000

Previous 8,000 -0.0%

Holding current value

$2.71 Million

Previous $2.26 Million 25.94%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 25, 2023	BUY	$203.88 - $312.0 $448,536 - $686,400	2,200 Added 37.93%	8,000 $1.76 Million
Q4 2022 Feb 01, 2023	BUY	$58.39 - $296.54 $338,662 - $1.72 Million	5,800 New	5,800 $1.71 Million
Q3 2021 Oct 22, 2021	SELL	$78.35 - $105.02 $2.02 Million - $2.7 Million	-25,750 Closed	0 $0
Q2 2021 Aug 05, 2021	BUY	$97.2 - $137.59 $1.17 Million - $1.65 Million	12,000 Added 87.27%	25,750 $2.49 Million
Q1 2021 Apr 28, 2021	BUY	$108.54 - $125.2 $976,860 - $1.13 Million	9,000 Added 189.47%	13,750 $1.57 Million
Q4 2020 Mar 12, 2021	BUY	$110.06 - $133.7 $522,785 - $635,075	4,750 New	4,750 $515,000
Q2 2019 Aug 01, 2019	SELL	$91.13 - $142.5 $533,110 - $833,625	-5,850 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$103.48 - $143.84 $605,358 - $841,464	5,850 New	5,850 $1.4 Million
Q4 2018 Feb 12, 2019	SELL	$94.77 - $215.54 $554,404 - $1.26 Million	-5,850 Closed	0 $0
Q3 2018 Nov 09, 2018	SELL	$207.3 - $300.31 $31,095 - $45,046	-150 Reduced 2.5%	5,850 $0
Q2 2018 Aug 14, 2018	BUY	$101.55 - $313.9 $609,300 - $1.88 Million	6,000 New	6,000 $1.67 Million
Q1 2018 May 03, 2018	SELL	$93.35 - $149.04 $186 - $298	-2 Closed	0 $0
Q3 2017 Nov 06, 2017	BUY	$15.48 - $46.19 $30 - $92	2	2 $0

Others Institutions Holding MDGL

# of Institutions

296

Shares Held

22M

Call Options Held

819K

Put Options Held

640K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.8B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.

Account

Deka Bank Deutsche Girozentrale Madrigal Pharmaceuticals, Inc. Transaction History